Timely Cessation of Proton Pump Inhibitors in Critically Ill Patients Impacts Morbidity and Mortality: A Propensity Score-Matched Cohort Study*

Lars Palmowski,Alexander von Busch,Matthias Unterberg,Lars Bergmann,Stefanie Schmitz,Andreas Schlüter,Jürgen Peters,Michael Adamzik,Tim Rahmel

DOI: https://doi.org/10.1097/ccm.0000000000006104

IF: 8.8

2024-01-20

Critical Care Medicine

Abstract:Proton pump inhibitors (PPIs) are among the most commonly prescribed medications, usually with a short-term indication and a recommended duration of less than 8 weeks ( 1–3 ). A major short-term indication is stress ulcer prophylaxis (SUP) ( 4 ), especially in ICUs, where certain critically ill patients are at increased risk of gastrointestinal bleeding ( 5–7 ). Although there is controversy about which patients in the ICU benefit from SUP, the latter is currently initiated in up to 90% of all critically ill patients ( 8–12 ). However, regardless of the debate on which ICU patients should receive PPI therapy, its timely cessation once the indication has expired is of utmost importance since PPI therapies not only result in an economic burden but may also evoke serious side effects ( 3 , 13 , 14 ). Greater risk of clostridium difficile infection ( 15–18 ), gastritis ( 17 ), pneumonia ( 15 ), cardiovascular events ( 19 , 20 ), chronic renal failure ( 21 , 22 ), greater frequency of various neoplasms ( 23–27 ), possibly malabsorption disorders evoking vitamin B12 deficiency ( 28 , 29 ), hypocalcemia ( 30 ), and hypomagnesemia ( 30 ) are specific predescribed side effects of a long-term PPI therapy. Even an increased risk of mortality has been observed in retrospective studies ( 31–34 ).

critical care medicine